Premium
P3–309: Enrichment of insoluble tau from progressive supranuclear palsy brain tissue
Author(s) -
Wray Selina,
Revesz Tamas,
Holton Janice L.,
Anderton Brian H.,
Hanger Diane P.
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.1579
Subject(s) - progressive supranuclear palsy , chemistry , tau protein , tauopathy , differential centrifugation , centrifugation , corticobasal degeneration , phosphorylation , biochemistry , alzheimer's disease , neurodegeneration , pathology , disease , medicine
and -synuclein transgenic mice hippocampus. Pathology is observed by immunohistochemistry using specific antibodies which detect tau hyperphosphorylation, A or -synuclein. Pathology is observed at different time points, mainly seven month and one year post-injection. We are studying the effects of time, different brain regions and age of animals on the development of tangles. Results: LV-Tau injected mice show high Tau expression localized in various layers of the hippocampus. In addition, phosphorylated Tau is found in cell bodies and neurites in the area of Dentate gyrus and the CA1 layer. Already at two months post-injection, we find cells positive for AT8 staining which detects hyperphosphorylated tau. This number is increased at 4 months postinjection and much higher at 7 months. In APP23 transgenic mice, the levels of AT8 positive cells seem higher compared to wt injected mice 4 months post-injection. Conclusion: We observe high lentivirus-mediated expression in vivo within the hippocampus. Tau phosphorylation increases with time and correlates well with protein expression levels. This in vivo model, as an alternative to transgenic animals, may allow us to demonstrate a synergy between extracellular A deposits and intracellular hyperphosphorylated Tau filaments and also study an interaction between -synuclein and Tau proteins.